

## Supplementary Material

### Rare pathogenic variants in G-protein coupled receptor genes involved in gut-to-host communication are associated with cardiovascular disease risk

**Short title:** Gut-to-host receptors and cardiovascular disease risk

Leticia Camargo Tavares<sup>1,2\*</sup>; Rikeish R. Muralitharan<sup>1,2</sup>; Matthew Snelson<sup>1,2</sup>; Francine Z. Marques<sup>1,2,3\*</sup>

<sup>1</sup>Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Australia; <sup>2</sup>Victorian Heart Institute, Monash University, Melbourne, Australia; <sup>3</sup>Baker Heart and Diabetes Institute, Melbourne, Australia

**\*Corresponding authors:** Dr Leticia Camargo Tavares, PhD, Postdoctoral Research Fellow, Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Australia. Email: [leticia.camargotavares1@monash.edu](mailto:leticia.camargotavares1@monash.edu); Prof Francine Z. Marques, PhD, Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Australia, Phone: +61-03-9905 6958. E-mail: [francine.marques@monash.edu](mailto:francine.marques@monash.edu)

**Funding Information:** F.Z.M. is supported by a Senior Medical Research Fellowship from the Sylvia and Charles Viertel Charitable Foundation, a National Heart Foundation Future Leader Fellowship (105663), and National Health & Medical Research Council (NHMRC) Emerging Leader Fellowship (GNT2017382). M.S. is supported by a National Heart Foundation Postdoctoral Fellowship (106698).

### **Conflict of interest**

None.

### **Data availability**

This research has been conducted using the UK Biobank Resource under Application Number 86879. This work uses data provided by patients and collected by the NHS as part of their care and support.

### **Acknowledgement**

We would like to acknowledge Monash Bioinformatics Platform for access to the M3 servers, as well as the participants of the UK Biobank. This research has been conducted using the UK Biobank Resource under Application Number 86879.

### **Author contributions**

LCT led and FZM supported study design and conception; LCT led the formal data analysis and visualization; LCT led and RRM, MS, and FZM supported data interpretation; LCT led and RRM, MS, and FZM supported drafting the manuscript; All authors approved the final version of the manuscript.

### **Keywords**

Genomics; Rare variants; G-protein couple receptors; Short-chain fatty acids; Hypertension; Major adverse cardiac events.

# Supplementary Material

## Supplementary Methods

UK Biobank study subjects.....	4
Phenotypes definition.....	4
Identification of rare pathogenic variants in SCFA-sensing GPCR genes.....	5
Association analyses between RPVs carriership and phenotype risk.....	6
Comorbidity analyses.....	7
Fiber analyses.....	7
References.....	9

## Supplementary Tables

Table S1.....	11
Table S2.....	12
Table S3.....	13
Table S4.....	14
Table S5.....	15
Table S6.....	22
Table S7.....	23
Table S8.....	24
Table S9.....	26
Table S10.....	27
Table S11.....	28
Table S12.....	29

## Supplementary Methods

### UK Biobank study subjects

The UK Biobank (UKBB) is a population-based longitudinal cohort of >500,000 participants aged between 40 and 69 years, with available genotype, demographic and health-related data.<sup>1</sup> Health information encompasses electronic medical records (EMR) from hospital inpatient admissions, questionnaire data about general health and lifestyle, and self-report of medical diagnoses and medication usage. UKBB follows the principles of the Declaration of Helsinki and received ethical approval from the competent Research Ethics Committee (REC reference for UKBB is 11/NW/0382). The data was obtained under Application Number 86879 from UKBB.

Upon exclusion of individuals with withdrawn consent, sex mismatches (genetic versus reported), with excess relatives (>10 relatives with kinship $\geq$ 0.0442) and of non-white-European genetic ancestry, a total of 393,649 participants with whole-exome sequencing (WES) data were included in downstream analyses (**Table S1**). Given the limited representation of individuals from other populations in the UKBB and to ensure meaningful statistical power, our analyses were restricted to individuals of white European genetic ancestry (identified through the data-field 22006).

### Phenotype definitions

Participants were identified as patients (cases) with essential hypertension or major adverse cardiac events (MACE), including acute coronary syndrome (ACS), heart failure (HF), and ischemic stroke, as previously reported.<sup>2</sup> For each phenotype of interest, controls were defined as participants without the condition. UKBB data-fields utilized for hypertension and MACE phenotype definitions encompassed electronic medical records from hospital inpatient

(either primary or secondary) episodes (data field 41270), self-reported medical diagnoses (data field 20002), death registers (data fields 40001 and 40002), and surgical records (data fields 41272 and 20004) related to revascularization procedures, including percutaneous coronary intervention or coronary artery bypass graft (detailed in **Table S2**). Specifically, essential hypertension was identified based on the hospital-inpatient records bearing the ICD-10 (International Classification of Diseases, 10th revision) code "I10" or through self-reported medical history (codes 1065 or 1072). The occurrence of MACE is recognized to be associated with SMuRFs, including hypertension, smoking, diabetes, and hypercholesterolemia.<sup>3</sup> The definitions of SMuRFs were determined based on inpatient diagnoses from medical records, self-reported medical histories, or the self-reported usage of insulin or cholesterol-lowering medication, as described in **Table S3**. Demographic and clinical characteristics of the study cohort are shown in **Table S4**.

### **Identification of rare pathogenic variants (RPVs) in SCFA-sensing GPCR genes**

UKBB WES data were produced using the IDT xGen Exome Research Panel v1.0 on Illumina NovaSeq 6000 platform, which targets 39 megabases of the human genome (19,396 genes), with 20X coverage at 95% of sites on average.<sup>4</sup> Rare (minor allele frequency <1%) DNA variants in short-chain fatty acid (SCFA)-sensing G-protein coupled receptor (GPCR) genes were extracted from PLINK-formatted WES data (UKBB category 170) based on genomic coordinates encompassing *FFAR3*/GPR41, *FFAR2*/GPR43 and *HCAR2*/GPR109A gene regions according to the GRCh38 human genome build. Markers with call rates <95% were excluded. Variants' functional consequences were annotated with Ensembl Variant Effect Predictor (VEP, release 112, <http://www.ensembl.org/info/docs/tools/vep>).<sup>5</sup> Pathogenic variants were identified using two classification criteria: (1) '*high-impact functional consequence*', which includes stop gained/lost, frameshift, and splicing alterations based on Ensembl transcripts and Sequence Ontology terms

([https://asia.ensembl.org/info/genome/variation/prediction/predicted\\_data.html](https://asia.ensembl.org/info/genome/variation/prediction/predicted_data.html))<sup>5</sup>; (2)

‘*pathogenic missense variants*’, which includes missense variants with pathogenic likelihood scores >0.564 from AlphaMissense (<http://alphamissense.hegelab.org>)<sup>6</sup>, >0.025 from M-CAP (Mendelian Clinically Applicable Pathogenicity, <http://bejerano.stanford.edu/MCAP>)<sup>7</sup>, or >20 from CADD (Combined Annotation Dependent Depletion, <http://cadd.gs.washington.edu/>)<sup>8</sup> classifiers, as similarly performed previously.<sup>9</sup> In total, 158 variants were identified as rare pathogenic variants (RPVs) and included in downstream association analyses: 25 in *FFAR3*/*GPR41* (24% high-impact, 76% pathogenic missense), 71 in *FFAR2*/*GPR43* (20% high-impact, 80% pathogenic missense), and 62 in *HCAR2*/*GPR109A* (16% high impact, 84% pathogenic missense). VEP annotations are described in **Table S5**.

### **Association analyses between RPVs carriership and phenotype risk**

Multiple and single GPCR gene-based analyses were conducted to test whether the presence of RPVs that disrupt gene function is associated with increased phenotype risk (based on one-tailed statistics), using multivariable-adjusted logistic regression models implemented in R (*glm* function). For these analyses, UKBB cases and controls were stratified into carriers of RPVs in any GPCR gene (for multiple gene-based analysis) or carriers of RPVs in individual GPCR genes (for single gene-based analysis) and compared with their respective non-carriers (**Table S6**). Age- and sex-adjusted models were conducted, either excluding or including BMI as a covariate (*model 1* and *model 2*, respectively). Given the occurrence of MACE is recognized to be associated with SMuRFs, we further adjusted MACE analyses for these additional covariates (*model 3*). Genetic ancestry captured by the 10-top genetic principal components (extracted as pre-computed PCs from data field 22020) was also included as covariate when testing the association between GPCR RPVs and phenotypes’ risk, to account for population structure effects. Multiple comparisons were corrected by false discovery rate using the Benjamini-Hochberg method (threshold  $q < 0.05$ ) to control for type I error,

accounting for three GPCR genes and distinct models for each phenotype of interest. Full results are shown in **Table S7** (multiple gene-based analysis) and **Table S8** (single gene-based analysis).

### **Comorbidity analyses**

To identify other diseases and conditions that are more common among hypertension and MACE patients carrying GPCR RPVs (compared to non-carriers) and could contribute to RPVs-phenotype risk associations, we performed a comorbidity analysis by retrieving hospital inpatient records for 1,259 ICD-10 codes (Chapters I–XIV) across 39,563,559 data-points (243 data-fields covering 162,813 cases for hypertension/MACE). Only ICD-10 diseases with a prevalence greater than 1% were included, resulting in 297 ICD-10 diseases in the analyses. Age- and sex-adjusted models, either excluding or including BMI as a covariate (*model 1* and *model 2*, respectively), were applied to compare the prevalence of these ICD-10 comorbid diseases within cases of each phenotype of interest (n=162,813) stratified as GPCR RPVs carriers versus non-carriers. Demographic and clinical characteristics are detailed in **Table S9**. FDR adjustment for multiple comparisons was applied, accounting for 297 ICD-10 diseases and two models. Statistically significant results are shown in **Table S10**.

### **Fiber analyses**

To further understand the complex relationship between fiber, gut-to-host communication, and cardiovascular health, we investigated whether carrying GPCR RPVs increases the risk of hypertension and MACE among individuals consuming an adequate-fiber diet. To estimate daily fiber intake, we studied a subset of UK Biobank participants with dietary data, assessed by a 24-hour dietary recall of food intake on the previous day in five different instances (n=168,142 with dietary data available for at least one instance). Based on nutritional recommendations,<sup>10</sup> an adequate-fiber diet was defined as an average intake of  $\geq 25$  g/day for

women and  $\geq 30$  g/day for men, leaving 13,858 participants for subsequent analyses.

Demographic and clinical characteristics of this subset are detailed in **Table S11**. Age- and sex-adjusted models, either excluding or including BMI as a covariate (*model 1* and *model 2*, respectively), were conducted to compare the prevalence of phenotypes of interest between GPCR RRVs carriers versus non-carriers among adequate-fiber consumers. Statistically significant findings (FDR adjusted) are shown in **Table S12**.

## References

1. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018;**562**:203-209.
2. Zheng T, Camargo Tavares L, D'Amato M, Marques FZ. Constipation is associated with an increased risk of major adverse cardiac events in a UK population. *Am J Physiol Heart Circ Physiol* 2024.
3. Figtree GA, Vernon ST, Hadziosmanovic N, Sundstrom J, Alfredsson J, Arnott C, Delatour V, Leosdottir M, Hagstrom E. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. *Lancet* 2021;**397**:1085-1094.
4. Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-Jauregui C, Khalid S, Ye B, Banerjee N, Li AH, O'Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L, Lopez A, Penn J, Habegger L, Blumenfeld AL, Bai X, O'Keefe S, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK, Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH, Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S, Cantor M, Nelson MR, Whittaker J, Reid JG, Marchini J, Overton JD, Scott RA, Abecasis GR, Yerges-Armstrong L, Baras A, Collaboration G-RD, Center RG. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature* 2020;**586**:749-756.
5. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The Ensembl Variant Effect Predictor. *Genome Biol* 2016;**17**:122.

6. Cheng J, Novati G, Pan J, Bycroft C, Žemgulytė A, Applebaum T, Pritzel A, Wong LH, Zielinski M, Sargeant T, Schneider RG, Senior AW, Jumper J, Hassabis D, Kohli P, Avsec Ž. Accurate proteome-wide missense variant effect prediction with AlphaMissense. *Science* 2023;**381**:eadg7492.
7. Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, Bernstein JA, Bejerano G. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat Genet* 2016;**48**:1581-1586.
8. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 2019;**47**:D886-D894.
9. Zheng T, Camargo-Tavares L, Bonfiglio F, Marques FZ, Naim HY, D'Amato M. Rare Hypomorphic Sucrase Isomaltase Variants in Relation to Irritable Bowel Syndrome Risk in UK Biobank. *Gastroenterology* 2021;**161**:1712-1714.
10. Jama HA, Snelson M, Schutte AE, Muir J, Marques FZ. Recommendations for the Use of Dietary Fiber to Improve Blood Pressure Control. *Hypertension* 2024;**81**:1450-1459.

## Supplementary Tables

**Table S1.** Individual quality control in the overall study cohort in UK Biobank.

Filtering step	Samples removed	Samples left
Initial number	0	502,411
Remove individuals with withdrawn consent	-231	502,180
WES data available	-32,598	469,582
Sex mismatch check	-477	469,105
Self-reported White individuals (British, Irish and other white)	-26,791	442,314
Genetic white-European individuals (based on principal component analysis)	-48,626	393,688
Remove individuals with excess (>10) putative third-degree relatives (kinship $\geq$ 0.0442)	-39	<b>393,649</b>

**Table S2.** Phenotype definitions and their associated data-field and coding in UK Biobank.

Phenotype definition	HTN	ACS	Stroke	HF
<b>Hospital inpatient diagnosis (ICD-10)</b>	41270 in (I10.*)	41270 in (I20.0, I21.*, I24.8, I24.9)	41270 in (I63.*, I64.*)	41270 in (I50.*)
<b>Self-reported medical history</b>	20002 in (1065, 1072)	20002 in (1075)	20002 in (1081, 1583)	20002 in (1076)
<b>Surgical code (OPCS-4)</b>	-	41272 in (K40.*, K41.*, K42.*, K43.*, K44.*, K45.*, K46.*, K49.*, K50.*, K75.*)	-	-
<b>Self-reported surgical history</b>	-	20004 in (1070, 1095)	-	-
<b>Death register</b>	-	40001 in (I20.0, I21.*, I24.8, I24.9) or 40002 in (I20.0, I21.*, I24.8, I24.9)	40001 in (I63.*, I64.*) or 40002 in (I63.*, I64.*)	40001 in (I50.*) or 40002 in (I50.*)
<p><b>Legend:</b> Phenotype definitions associated data-field and coding in UK Biobank are shown as ‘data-field number in (coding number)’  <b>ACS:</b> Acute coronary syndrome; <b>HTN:</b> Essential hypertension; <b>HF:</b> Heart failure; <b>ICD:</b> International Classification of Diseases; <b>OPCS:</b> Operating Procedure Codes Supplement.</p>				

**Table S3.** Standard modifiable cardiovascular risk factors (SMuRFs) definitions and their associated data-field and coding in UK Biobank.

Phenotype definition	Smoking (current or past)	HTN	Diabetes	Hypercholesterolaemia
Hospital inpatient diagnosis (ICD-10)	-	41270 in (I10.*)	41270 in (E10.*, E11.*, E12.*, E13.*, E14.*)	41270 in (E78.0)
Self-reported medical history	-	20002 in (1065, 1072)	20002 in (1220, 1221, 1222, 1223)	-
Self-reported medication	-	-	6177 in (3)	6177 in (1)
Smoking lifestyle	1239 in (1) or 1249 in (1)	-	-	-
<p><b>Legend:</b> Phenotype definitions associated data-field and coding in UK Biobank are shown as ‘data-field number in (coding number)’  <b>HTN:</b> Essential hypertension; <b>ICD:</b> International Classification of Diseases.</p>				

**Table S4.** Study cohort demographic and clinical characteristics (n=393,649).

	HTN		ACS		Stroke		HF		MACE	
	controls	cases	controls	cases	controls	cases	controls	cases	controls	cases
N of participants	241,884	151,765	364,982	28,667	381,280	12,369	379,597	14,052	348,138	45,511
Women (n, %)	141,134 (58.3)	71,584 (47.2)	205,130 (56.2)	7,588 (26.5)	207,841 (54.5)	48,77 (39.4)	207,803 (54.7)	4,915 (35.0)	197,861 (56.8)	14,857 (32.6)
Age, years (mean, SD)	55.07 (8.06)	59.85 (6.96)	56.58 (8.02)	61.18 (6.43)	56.77 (8.00)	61.48 (6.50)	56.72 (8.00)	62.30 (6.00)	56.34 (8.01)	61.30 (6.45)
BMI, kg/m <sup>2</sup> (mean, SD)	26.39 (4.21)	29.05 (5.08)	27.30 (4.72)	28.90 (4.75)	27.38 (4.73)	28.61 (5.00)	27.33 (4.68)	29.82 (5.74)	27.22 (4.67)	28.92 (5.03)
SBP, mmHG (mean, SD)	134.33 (17.36)	149.48 (19.42)	139.90 (19.54)	144.10 (20.23)	140.04 (19.56)	145.19 (20.73)	140.02 (19.53)	145.14 (21.37)	139.63 (19.45)	144.60 (20.40)
DBP, mmHG (mean, SD)	79.83 (9.76)	86.09 (10.85)	82.29 (10.60)	81.80 (11.19)	82.22 (10.62)	83.18 (11.26)	82.26 (10.60)	82.07 (11.66)	82.23 (10.57)	82.40 (11.22)
Smoking (current or past)	69,997 (28.9)	58,082 (38.3)	113,954 (31.2)	14,125 (49.3)	122,407 (32.1)	5,672 (45.9)	121,062 (31.9)	7,017 (49.9)	106,536 (30.6)	21,543 (47.3)
HTN (n, %)	0 (0.0)	151,765 (100.0)	129,456 (35.5)	22,309 (77.8)	142,578 (37.4)	9,187 (74.3)	140,422 (37.0)	11,343 (80.7)	117,302 (33.7)	34,463 (75.7)
Diabetes (n, %)	7,622 (3.2)	26,994 (17.8)	27,695 (7.6)	6,921 (24.1)	31,806 (8.3)	2,810 (22.7)	30,330 (8.0)	4,286 (30.5)	24,115 (6.9)	10,501 (23.1)
Hypercholesterolemia (n, %)	20,875 (8.6)	59,971 (39.5)	60,530 (16.6)	20,316 (70.9)	74,002 (19.4)	6,844 (55.3)	72,775 (19.2)	8,071 (57.4)	52,896 (15.2)	27,950 (61.4)
Any SMuRF (n, %)	85,398 (35.3)	151,765 (100.0)	210,340 (57.6)	26,823 (93.6)	226,078 (59.3)	11,085 (89.6)	224,160 (59.1)	13,003 (92.5)	195,517 (56.2)	41,646 (91.5)

**Legend:** ACS: Acute coronary syndrome; BMI: Body mass index; HTN: Essential hypertension; HF: Heart failure; MACE: Major adverse cardiac events; SD: Standard deviation; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; SMuRFs: Standard modifiable cardiovascular risk factor, including smoking, HTN, diabetes, and hypercholesterolemia.

**Table S5.** GPCR RPVs annotations obtained with the Ensembl Variant Effect Predictor tool.

GPCR gene	Variant (CHR:BP:OA:EA)	rsID	MAF	Pathogenic group	Functional consequence	Protein position	Amino acid change	AlphaMissense score	M-CAP score	CADD phred score
<i>HCAR2</i>	12:122702192:T:G		1.270E-06	High-impact	stop_lost	364	*/Y			6.18
<i>HCAR2</i>	12:122702194:A:C		1.270E-06	High-impact	stop_lost	364	*/E			4.83
<i>HCAR2</i>	12:122702381:A:C		2.540E-06	Pathogenic missense	missense_variant	301	F/L	0.9724	0.0441	15.18
<i>HCAR2</i>	12:122702413:G:T		1.270E-06	Pathogenic missense	missense_variant	291	P/T	0.9632	0.5408	25.1
<i>HCAR2</i>	12:122702516:C:G		5.081E-06	Pathogenic missense	missense_variant	256	W/C	0.6014	0.0147	22.5
<i>HCAR2</i>	12:122702516:C:T		3.811E-06	High-impact	stop_gained	256	W/*			35
<i>HCAR2</i>	12:122702533:G:A	rs776840309	5.081E-06	Pathogenic missense	missense_variant	251	R/W	0.6285	0.0664	23.9
<i>HCAR2</i>	12:122702542:C:G	rs775536264	2.540E-06	Pathogenic missense	missense_variant	248	V/L	0.7207	0.0102	22.1
<i>HCAR2</i>	12:122702543:G:T	rs201091527	1.816E-04	Pathogenic missense	missense_variant	247	S/R	0.996	0.1751	17.47
<i>HCAR2</i>	12:122702544:C:T	rs1877107348	5.081E-06	Pathogenic missense	missense_variant	247	S/N	0.9134	0.062	24.6
<i>HCAR2</i>	12:122702554:A:G	rs202134216	8.764E-05	Pathogenic missense	missense_variant	244	F/L	0.9982	0.2401	26.7
<i>HCAR2</i>	12:122702609:C:A	rs201310632	1.232E-04	Pathogenic missense	missense_variant	225	K/N	0.7504	0.018	22.8
<i>HCAR2</i>	12:122702629:G:A	rs200587011	7.621E-06	High-impact	stop_gained	219	Q/*			35
<i>HCAR2</i>	12:122702659:C:G		2.540E-06	Pathogenic missense	missense_variant	209	A/P	0.6986	0.0439	16.79
<i>HCAR2</i>	12:122702665:A:G		1.270E-06	Pathogenic missense	missense_variant	207	C/R	0.9928	0.0552	26.3
<i>HCAR2</i>	12:122702697:T:A		1.270E-06	Pathogenic missense	missense_variant	196	E/V	0.6775	0.1527	25.2
<i>HCAR2</i>	12:122702700:A:G	rs200492929	5.081E-06	Pathogenic missense	missense_variant	195	L/P	0.8108	0.0432	26.3
<i>HCAR2</i>	12:122702716:C:T	rs200721962	8.891E-06	Pathogenic missense	missense_variant	190	E/K	0.5779	0.0133	17.62
<i>HCAR2</i>	12:122702720:C:G	rs1341264802	2.540E-06	Pathogenic missense	missense_variant	188	W/C	0.9514	0.0845	24.5
<i>HCAR2</i>	12:122702736:C:G	rs201831072	7.621E-06	Pathogenic missense	missense_variant	183	C/S	0.9159	0.0192	20.3
<i>HCAR2</i>	12:122702754:C:T	rs1194187180	2.540E-06	Pathogenic missense	missense_variant	177	C/Y	0.9819	0.2813	22.8
<i>HCAR2</i>	12:122702754:CA:C		1.270E-06	High-impact	frameshift_variant	177	C/X			
<i>HCAR2</i>	12:122702814:C:T		1.270E-06	Pathogenic missense	missense_variant	157	G/D	0.8723	0.0222	18.62

HCAR2	12:122702825:GC:G		1.270E-06	High-impact	frameshift_variant	153	G/X			
HCAR2	12:122702841:G:A		1.270E-06	Pathogenic missense	missense_variant	148	S/F	0.9559	0.045	26.2
HCAR2	12:122702899:C:G		7.621E-06	Pathogenic missense	missense_variant	129	V/L	0.9334	0.1078	23
HCAR2	12:122702902:G:A	rs201756503	6.351E-06	Pathogenic missense	missense_variant	128	R/W	0.6971	0.089	23.2
HCAR2	12:122702919:G:A	rs200705418	1.143E-05	Pathogenic missense	missense_variant	122	A/V	0.7908	0.1984	24.7
HCAR2	12:122702928:G:C		1.143E-05	Pathogenic missense	missense_variant	119	T/R	0.9815	0.2598	24.2
HCAR2	12:122702933:G:T	rs199839290	1.270E-05	Pathogenic missense	missense_variant	117	F/L	0.9802	0.0119	26.2
HCAR2	12:122702940:A:T		1.270E-06	Pathogenic missense	missense_variant	115	I/N	0.9087	0.2487	25.2
HCAR2	12:122702947:C:T		1.270E-06	Pathogenic missense	missense_variant	113	G/S	0.5859	0.0425	24.4
HCAR2	12:122702953:G:A	rs753670084	3.811E-06	Pathogenic missense	missense_variant	111	R/C	0.9087	0.1627	26.7
HCAR2	12:122702963:C:A	rs752639607	6.351E-06	Pathogenic missense	missense_variant	107	L/F	0.6978	0.0438	22.1
HCAR2	12:122702964:A:C	rs1234650625	1.270E-06	Pathogenic missense	missense_variant	107	L/W	0.8949	0.104	25.9
HCAR2	12:122702982:C:G		1.270E-06	Pathogenic missense	missense_variant	101	R/P	0.9474	0.1481	24.2
HCAR2	12:122702983:G:A	rs200794525	1.016E-05	Pathogenic missense	missense_variant	101	R/W	0.6352	0.1087	24.1
HCAR2	12:122702997:C:T		1.270E-06	Pathogenic missense	missense_variant	96	G/E	0.671	0.0267	23.3
HCAR2	12:122702999:A:C		1.270E-06	Pathogenic missense	missense_variant	95	F/L	0.9333	0.0251	20.8
HCAR2	12:122703006:C:T	rs770293961	1.270E-06	High-impact	stop_gained	93	W/*			36
HCAR2	12:122703011:C:T		1.270E-06	High-impact	stop_gained	91	W/*			27.8
HCAR2	12:122703015:C:G	rs200252776	8.891E-06	Pathogenic missense	missense_variant	90	R/P	0.6079	0.0158	10.97
HCAR2	12:122703026:G:T		7.621E-06	Pathogenic missense	missense_variant	86	N/K	0.9259	0.041	13.16
HCAR2	12:122703028:T:C		3.811E-06	Pathogenic missense	missense_variant	86	N/D	0.6015	0.058	18.32
HCAR2	12:122703033:A:T	rs1396108170	3.811E-06	Pathogenic missense	missense_variant	84	M/K	0.7304	0.0111	7.774
HCAR2	12:122703057:A:G	COSV105903496	1.270E-06	Pathogenic missense	missense_variant	76	L/P	0.9889	0.1396	25.6
HCAR2	12:122703070:C:T	COSV61024552	1.270E-06	Pathogenic missense	missense_variant	72	A/T	0.623	0.1256	25.2
HCAR2	12:122703080:G:C		1.270E-06	Pathogenic missense	missense_variant	68	N/K	0.9954	0.0167	25.5
HCAR2	12:122703096:C:G		1.270E-06	Pathogenic missense	missense_variant	63	R/P	0.8998	0.0213	23
HCAR2	12:122703100:T:G	rs530458347	2.540E-06	Pathogenic missense	missense_variant	62	S/R	0.9809	0.0634	25.9

<i>HCAR2</i>	12:122703126:C:T		1.270E-06	Pathogenic missense	missense_variant	53	C/Y	0.6438	0.0114	25.1
<i>HCAR2</i>	12:122703142:C:T		1.270E-06	Pathogenic missense	missense_variant	48	A/T	0.8578	0.0417	25.5
<i>HCAR2</i>	12:122703147:C:T		1.270E-06	Pathogenic missense	missense_variant	46	G/D	0.9864	0.016	24.1
<i>HCAR2</i>	12:122703150:T:A	rs763999055	1.270E-06	Pathogenic missense	missense_variant	45	N/I	0.9688	0.484	25.7
<i>HCAR2</i>	12:122703154:C:A	rs767733941	1.270E-06	Pathogenic missense	missense_variant	44	G/C	0.8324	0.046	24.1
<i>HCAR2</i>	12:122703163:C:G	rs1348029018	1.270E-06	Pathogenic missense	missense_variant	41	G/R	0.9955	0.1124	23.9
<i>HCAR2</i>	12:122703163:C:T	rs1348029018	1.270E-06	Pathogenic missense	missense_variant	41	G/R	0.9955	0.1195	24
<i>HCAR2</i>	12:122703173:C:CT		1.270E-06	High-impact	frameshift_variant	37	E/EX			
<i>HCAR2</i>	12:122703177:A:G	rs780534579	6.351E-06	Pathogenic missense	missense_variant	36	L/P	0.9096	0.0848	23.3
<i>HCAR2</i>	12:122703181:C:T		1.270E-06	Pathogenic missense	missense_variant	35	G/R	0.9372	0.0403	23.4
<i>HCAR2</i>	12:122703192:G:A	rs141014410	7.621E-06	Pathogenic missense	missense_variant	31	P/L	0.6174	0.0439	24
<i>HCAR2</i>	12:122703220:G:A	rs764643885	6.351E-06	High-impact	stop_gained	22	R/*			35
<i>FFAR3</i>	19:35359043:C:A	rs372231935	1.270E-06	Pathogenic missense	missense_variant	51	D/E	0.6816	0.0075	17.83
<i>FFAR3</i>	19:35359071:G:A	rs139036566	2.159E-05	Pathogenic missense	missense_variant	61	D/N	0.6195	0.0353	25.2
<i>FFAR3</i>	19:35359105:T:C	rs202122950	8.358E-04	Pathogenic missense	missense_variant	72	M/T	0.6665	0.0196	24
<i>FFAR3</i>	19:35359133:G:A	rs759261993	1.524E-05	High-impact	stop_gained	81	W/*			35
<i>FFAR3</i>	19:35359183:C:T	rs1332664480	3.811E-06	Pathogenic missense	missense_variant	98	T/I	0.6887	0.0313	22.3
<i>FFAR3</i>	19:35359298:T:G		6.351E-06	Pathogenic missense	missense_variant	136	S/R	0.9858	0.0648	8.091
<i>FFAR3</i>	19:35359330:G:A	rs752926781	1.016E-05	Pathogenic missense	missense_variant	147	C/Y	0.7885	0.0143	25.9
<i>FFAR3</i>	19:35359396:G:A	rs370522843	3.811E-06	Pathogenic missense	missense_variant	169	C/Y	0.872	0.0634	24.9
<i>FFAR3</i>	19:35359419:C:T	rs546623697	7.621E-06	High-impact	stop_gained	177	Q/*			34
<i>FFAR3</i>	19:35359505:C:A	rs770864257	4.573E-05	Pathogenic missense	missense_variant	205	S/R	0.6682	0.015	22.6
<i>FFAR3</i>	19:35359529:AG:A	rs759936957	3.811E-06	High-impact	frameshift_variant	214	G/X			
<i>FFAR3</i>	19:35359579:C:A		2.540E-06	Pathogenic missense	missense_variant	230	T/K	0.8242	0.0146	24.1
<i>FFAR3</i>	19:35359592:C:G		6.351E-06	Pathogenic missense	missense_variant	234	F/L	0.9407	0.0157	23.4
<i>FFAR3</i>	19:35359600:G:C		2.540E-06	Pathogenic missense	missense_variant	237	C/S	0.6139	0.0147	25.5
<i>FFAR3</i>	19:35359604:T:G		3.811E-06	Pathogenic missense	missense_variant	238	F/L	0.9499	0.0426	22.4

<i>FFAR3</i>	19:35359605:G:A		2.540E-06	Pathogenic missense	missense_variant	239	G/R	0.9361	0.0465	26.1
<i>FFAR3</i>	19:35359621:C:T	rs561011815	8.891E-06	Pathogenic missense	missense_variant	244	S/F	0.8629	0.0604	24
<i>FFAR3</i>	19:35359625:T:G		1.270E-06	Pathogenic missense	missense_variant	245	H/Q	0.6576	0.0094	0.316
<i>FFAR3</i>	19:35359690:T:C	rs2066984319	6.351E-06	Pathogenic missense	missense_variant	267	L/P	0.7516	0.042	26.6
<i>FFAR3</i>	19:35359696:C:T	rs767908892	2.540E-06	Pathogenic missense	missense_variant	269	S/F	0.7431	0.0588	24.7
<i>FFAR3</i>	19:35359704:G:A	rs369542605	8.891E-06	Pathogenic missense	missense_variant	272	D/N	0.7315	0.0213	26.2
<i>FFAR3</i>	19:35359749:T:C	rs1261433323	5.081E-06	Pathogenic missense	missense_variant	287	F/L	0.572	0.0036	14.8
<i>FFAR3</i>	19:35359793:G:A		2.540E-06	High-impact	stop_gained	301	W/*			33
<i>FFAR3</i>	19:35359854:C:T	rs776486107	1.778E-05	High-impact	stop_gained	322	R/*			27.9
<i>FFAR3</i>	19:35359885:C:CA		2.540E-06	High-impact	frameshift_variant	332	S/SX			
<i>FFAR2</i>	19:35449746:T:C		1.270E-06	Pathogenic missense	missense_variant	11	L/P	0.6625	0.051	24.2
<i>FFAR2</i>	19:35449761:T:A		1.270E-06	Pathogenic missense	missense_variant	16	I/N	0.5785	0.0438	25.6
<i>FFAR2</i>	19:35449766:T:C		1.270E-06	Pathogenic missense	missense_variant	18	F/L	0.7472	0.0156	23.1
<i>FFAR2</i>	19:35449776:G:A	rs2067367647	1.270E-06	Pathogenic missense	missense_variant	21	G/D	0.9685	0.0433	28.3
<i>FFAR2</i>	19:35449779:T:TCCCTGCCAACCTCCTGGCCC		3.811E-06	High-impact	frameshift_variant	22	L/LPANLLAX			
<i>FFAR2</i>	19:35449789:C:A	rs533923897	7.621E-06	Pathogenic missense	missense_variant	25	N/K	0.9711	0.2488	23.2
<i>FFAR2</i>	19:35449794:TG:T		3.811E-06	High-impact	frameshift_variant	27	L/X			
<i>FFAR2</i>	19:35449796:G:A		1.270E-06	Pathogenic missense	missense_variant	28	A/T	0.6035	0.0363	27.7
<i>FFAR2</i>	19:35449851:T:C	rs771538131	1.270E-06	Pathogenic missense	missense_variant	46	I/T	0.7425	0.0603	26.2
<i>FFAR2</i>	19:35449854:T:G		1.270E-06	Pathogenic missense	missense_variant	47	L/R	0.8835	0.1254	26.7
<i>FFAR2</i>	19:35449863:G:T		1.270E-06	Pathogenic missense	missense_variant	50	S/I	0.8803	0.0597	23.3
<i>FFAR2</i>	19:35449869:C:A	rs1253813043	2.540E-06	Pathogenic missense	missense_variant	52	T/K	0.9398	0.0594	25.3
<i>FFAR2</i>	19:35449872:T:C		1.270E-06	Pathogenic missense	missense_variant	53	L/P	0.896	0.0707	27.4
<i>FFAR2</i>	19:35449877:G:A	rs747543025	3.938E-05	Pathogenic missense	missense_variant	55	D/N	0.8827	0.1327	31
<i>FFAR2</i>	19:35449916:G:A	rs765581638	5.081E-06	Pathogenic missense	missense_variant	68	E/K	0.8934	0.0574	24.9
<i>FFAR2</i>	19:35449916:G:C		1.270E-06	Pathogenic missense	missense_variant	68	E/Q	0.5731	0.0426	24.1
<i>FFAR2</i>	19:35449918:G:C		1.270E-06	Pathogenic missense	missense_variant	68	E/D	0.8989	0.0543	22.5

<i>FFAR2</i>	19:35449942:CCTGCCCAAGGTCGT:C	rs753777712	6.351E-06	High-impact	frameshift_variant	77-81	LPKVV/X			25.4
<i>FFAR2</i>	19:35449967:AC:A		2.540E-06	High-impact	frameshift_variant	85	T/X			
<i>FFAR2</i>	19:35449971:GT:G	rs1433117229	6.478E-05	High-impact	frameshift_variant	86	S/X			
<i>FFAR2</i>	19:35449974:T:C		2.540E-06	Pathogenic missense	missense_variant	87	F/S	0.7633	0.048	25.6
<i>FFAR2</i>	19:35449976:G:C	rs200320229	1.080E-04	Pathogenic missense	missense_variant	88	G/R	0.9719	0.018	23.7
<i>FFAR2</i>	19:35449979:T:G	rs1338150311	2.540E-06	Pathogenic missense	missense_variant	89	F/V	0.8007	0.0578	26.3
<i>FFAR2</i>	19:35449989:G:A	rs372925283	1.778E-05	Pathogenic missense	missense_variant	92	S/N	0.7506	0.0085	23.4
<i>FFAR2</i>	19:35450016:C:A	rs763737717	5.716E-05	Pathogenic missense	missense_variant	101	A/E	0.9186	0.0855	24.9
<i>FFAR2</i>	19:35450030:G:A	rs140779660	3.811E-06	Pathogenic missense	missense_variant	106	E/K	0.8892	0.0717	27.7
<i>FFAR2</i>	19:35450030:G:C	rs140779660	1.270E-05	Pathogenic missense	missense_variant	106	E/Q	0.6105	0.0315	26.1
<i>FFAR2</i>	19:35450033:C:CT		1.270E-06	High-impact	frameshift_variant	107	R/LX			
<i>FFAR2</i>	19:35450033:C:T	rs150111307	1.143E-05	Pathogenic missense	missense_variant	107	R/C	0.7818	0.4213	29
<i>FFAR2</i>	19:35450034:G:A	rs758560714	3.811E-06	Pathogenic missense	missense_variant	107	R/H	0.6966	0.2659	30
<i>FFAR2</i>	19:35450034:G:T	rs758560714	1.270E-06	Pathogenic missense	missense_variant	107	R/L	0.836	0.3919	31
<i>FFAR2</i>	19:35450045:G:T		1.270E-06	Pathogenic missense	missense_variant	111	V/L	0.7195	0.0495	25.4
<i>FFAR2</i>	19:35450052:T:C	rs1044871339	5.081E-06	Pathogenic missense	missense_variant	113	F/S	0.8855	0.032	24.5
<i>FFAR2</i>	19:35450116:G:T	rs1029056131	2.540E-06	Pathogenic missense	missense_variant	134	W/C	0.8036	0.3124	24.1
<i>FFAR2</i>	19:35450123:T:C	rs780672443	2.540E-06	Pathogenic missense	missense_variant	137	S/P	0.7827	0.0424	24.8
<i>FFAR2</i>	19:35450126:T:C	rs1298865522	7.621E-06	Pathogenic missense	missense_variant	138	F/L	0.6622	0.0066	21.8
<i>FFAR2</i>	19:35450130:G:A		2.540E-06	Pathogenic missense	missense_variant	139	G/D	0.9337	0.0128	24.4
<i>FFAR2</i>	19:35450137:C:A	rs769108749	2.540E-06	High-impact	stop_gained	141	C/*			35
<i>FFAR2</i>	19:35450144:G:A	rs1251799501	2.540E-06	Pathogenic missense	missense_variant	144	V/M	0.6047	0.0163	24.2
<i>FFAR2</i>	19:35450148:T:A	rs779367504	3.811E-06	Pathogenic missense	missense_variant	145	I/N	0.6214	0.0618	23.2
<i>FFAR2</i>	19:35450177:C:T	rs1330779175	6.351E-06	High-impact	stop_gained	155	Q/*			33
<i>FFAR2</i>	19:35450204:T:G	rs2067371834	1.270E-06	Pathogenic missense	missense_variant	164	C/G	0.942	0.0723	24
<i>FFAR2</i>	19:35450228:C:T		3.811E-06	High-impact	stop_gained	172	Q/*			36
<i>FFAR2</i>	19:35450252:C:T		1.270E-06	Pathogenic missense	missense_variant	180	R/W	0.7406	0.0725	23.7

<i>FFAR2</i>	19:35450253:G:A	rs766489704	3.811E-06	Pathogenic missense	missense_variant	180	R/Q	0.652	0.0356	27.1
<i>FFAR2</i>	19:35450271:T:A	rs765896643	3.811E-06	Pathogenic missense	missense_variant	186	V/E	0.8507	0.0483	27
<i>FFAR2</i>	19:35450298:C:A		1.270E-06	Pathogenic missense	missense_variant	195	T/N	0.6187	0.0157	23.4
<i>FFAR2</i>	19:35450309:T:G		1.270E-06	Pathogenic missense	missense_variant	199	Y/D	0.7809	0.0999	28.3
<i>FFAR2</i>	19:35450316:G:GT		1.270E-06	High-impact	frameshift_variant	201	R/RX			
<i>FFAR2</i>	19:35450328:T:A		1.270E-06	Pathogenic missense	missense_variant	205	I/N	0.626	0.06	25.3
<i>FFAR2</i>	19:35450328:T:C	rs201319651	2.921E-05	Pathogenic missense	missense_variant	205	I/T	0.7213	0.015	24.4
<i>FFAR2</i>	19:35450369:C:G	rs1422005865	2.540E-06	Pathogenic missense	missense_variant	219	R/G	0.6559	0.0475	22.7
<i>FFAR2</i>	19:35450400:T:C		1.270E-06	Pathogenic missense	missense_variant	229	L/P	0.8908	0.0666	25.1
<i>FFAR2</i>	19:35450409:T:C	rs2067373826	8.891E-06	Pathogenic missense	missense_variant	232	L/P	0.9145	0.1695	25
<i>FFAR2</i>	19:35450420:G:A	rs143616979	3.899E-04	Pathogenic missense	missense_variant	236	G/R	0.9839	0.0735	23.2
<i>FFAR2</i>	19:35450435:T:C	rs2067374238	1.270E-06	Pathogenic missense	missense_variant	241	S/P	0.9808	0.0852	26.7
<i>FFAR2</i>	19:35450450:T:C	rs1419317668	1.143E-05	Pathogenic missense	missense_variant	246	Y/H	0.731	0.0107	22.8
<i>FFAR2</i>	19:35450468:C:T		5.081E-06	Pathogenic missense	missense_variant	252	P/S	0.7014	0.0555	23
<i>FFAR2</i>	19:35450476:G:T		1.270E-06	Pathogenic missense	missense_variant	254	W/C	0.9931	0.0883	26.5
<i>FFAR2</i>	19:35450477:C:T	rs1409706065	8.891E-06	Pathogenic missense	missense_variant	255	R/W	0.7596	0.1658	23.9
<i>FFAR2</i>	19:35450478:G:A	rs150050074	1.524E-05	Pathogenic missense	missense_variant	255	R/Q	0.6474	0.0396	23.8
<i>FFAR2</i>	19:35450507:A:G		1.270E-06	Pathogenic missense	missense_variant	265	N/D	0.8636	0.0296	24.3
<i>FFAR2</i>	19:35450511:C:A		1.270E-06	Pathogenic missense	missense_variant	266	A/D	0.9449	0.0946	23.1
<i>FFAR2</i>	19:35450514:G:A	rs775732916	6.351E-06	Pathogenic missense	missense_variant	267	S/N	0.7441	0.0243	18.68
<i>FFAR2</i>	19:35450520:AC:A		1.270E-06	High-impact	frameshift_variant	269	D/X			
<i>FFAR2</i>	19:35450522:C:A		1.270E-06	Pathogenic missense	missense_variant	270	P/T	0.8437	0.4397	23.5
<i>FFAR2</i>	19:35450528:C:T		1.270E-06	Pathogenic missense	missense_variant	272	L/F	0.582	0.0422	22.4
<i>FFAR2</i>	19:35450535:AT:A		1.271E-06	High-impact	frameshift_variant	274	Y/X			
<i>FFAR2</i>	19:35450540:T:C	rs1305066612	1.270E-06	Pathogenic missense	missense_variant	276	S/P	0.7511	0.025	24.8
<i>FFAR2</i>	19:35450653:CA:C		5.081E-06	High-impact	frameshift_variant	314	R/X			
<i>FFAR2</i>	19:35450692:CT:C		1.270E-06	High-impact	frameshift_variant	327	F/X			

**Legend:** Rare (minor allele frequency (MAF) <0.01) and pathogenic variants were identified using two classification criteria: (1) '*high-impact functional consequence*', which includes stop gained/lost, frameshift, and splicing alterations based on Ensembl Variant Effect Predictor annotations; (2) '*pathogenic missense variants*', which includes missense variants with pathogenic likelihood scores >0.564 from AlphaMissense, >0.025 from M-CAP (Mendelian Clinically Applicable Pathogenicity), or >20 from CADD (Combined Annotation Dependent Depletion) classifiers (highlighted in the table).

'Variant' is described as CHR:BP:OA:EA, where CHR is the chromosome position, BP is the base-pair position (GRCh38), OA is the reference allele and EA is the effect (minor) allele. MAF refers to the effect allele frequency in the UKBB cohort analysed (n=393,649), including only individuals of white-European genetic ancestry.

**GPCR:** G-protein couple receptor genes; **RPVs:** Rare pathogenic variants.

**Table S6.** SCFA-sensing GPCR rare pathogenic variants (RPVs) carriership.

	HTN		ACS		Stroke		HF		MACE	
	controls	cases	controls	cases	controls	cases	controls	cases	controls	cases
<b>GPCR RPVs carriers</b>										
<i>FFAR3 (GPR41)</i>	490 (0.20%)	318 (0.21%)	746 (0.20%)	62 (0.22%)	781 (0.21%)	27 (0.22%)	774 (0.20%)	34 (0.24%)	702 (0.20%)	106 (0.23%)
<i>FFAR2 (GPR43)</i>	413 (0.17%)	315 (0.21%)	662 (0.18%)	66 (0.23%)	700 (0.18%)	28 (0.23%)	701 (0.19%)	27 (0.19%)	626 (0.18%)	102 (0.22%)
<i>HCAR2 (GPR109A)</i>	267 (0.11%)	200 (0.13%)	427 (0.12%)	40 (0.14%)	451 (0.12%)	16 (0.13%)	439 (0.12%)	28 (0.20%)	399 (0.12%)	68 (0.15%)
Any GPCR ( <i>GPR 41/43/109A</i> )	1167 (0.48%)	836 (0.55%)	1833 (0.50%)	170 (0.59%)	1932 (0.51%)	71 (0.57%)	1914 (0.50%)	89 (0.63%)	1725 (0.50%)	278 (0.61%)
<b>Legend:</b> ‘GPCR RPVs carriers’ is described as n (%).										
<b>GPCR:</b> G-protein couple receptor genes; <b>HTN:</b> Essential hypertension; <b>ACS:</b> Acute coronary syndrome; <b>HF:</b> Heart failure; <b>MACE:</b> Major adverse cardiac events										

**Table S7.** Multiple gene-based analysis: associations between RPVs in any GPCR gene (*GPR 41/43/109A*) and risk of essential hypertension and MACE.

Phenotype	GPCR RPVs in controls (n, %)	GPCR RPVs in cases (n, %)	OR (95% CI)	P value	P <sub>FDR</sub>	Regression model
HTN	1167 (0.48%)	836 (0.55%)	<b>1.11 (1.01 - 1.22)</b>	<b>0.0149</b>	<b>0.0149</b>	model 1
			<b>1.12 (1.01 - 1.23)</b>	<b>0.0142</b>	<b>0.0149</b>	model 2
ACS	1833 (0.50%)	170 (0.59%)	1.13 (0.96 - 1.33)	0.0680	0.0828	model 1
			1.13 (0.96 - 1.33)	0.0690	0.0828	model 2
			1.12 (0.95 - 1.33)	0.0828	0.0828	model 3
Stroke	1932 (0.51%)	71 (0.57%)	1.10 (0.86 - 1.39)	0.2275	0.2277	model 1
			1.11 (0.87 - 1.41)	0.2044	0.2277	model 2
			1.10 (0.86 - 1.39)	0.2277	0.2277	model 3
HF	1914 (0.50%)	89 (0.63%)	1.21 (0.97 - 1.50)	0.0448	0.0679	model 1
			1.19 (0.95 - 1.48)	0.0641	0.0679	model 2
			1.18 (0.95 - 1.48)	0.0679	0.0679	model 3
MACE	1725 (0.50%)	278 (0.61%)	<b>1.19 (1.04 - 1.36)</b>	<b>0.0046</b>	<b>0.0085</b>	model 1
			<b>1.19 (1.04 - 1.36)</b>	<b>0.0061</b>	<b>0.0085</b>	model 2
			<b>1.18 (1.03 - 1.35)</b>	<b>0.0085</b>	<b>0.0085</b>	model 3

**Legend:** Summary statistics from multivariable logistic regression analyses testing the effect of RPV carriership status in any GPCR genes, compared between cases and controls for each phenotype of interest.

**model 1:** adjusted for age, sex, and 10 top genetic principal components.

**model 2:** adjusted for age, sex, BMI, and 10 top genetic principal components.

**model 3:** adjusted for age, sex, BMI, 10 top genetic principal components, and SMuRFs (only for MACE subtypes analyses)

**P<sub>FDR</sub>:** FDR adjustment for models per phenotype.

**GPCR:** G-protein couple receptor genes; **RPVs:** Rare pathogenic variants; **HTN:** Essential hypertension; **ACS:** Acute coronary syndrome; **HF:** Heart failure; **MACE:** Major adverse cardiac events; **OR:** odds ratio; **CI:** confidence interval; **SMuRFs:** Standard modifiable cardiovascular risk factor, including smoking, HTN, diabetes, and hypercholesterolemia.

**Table S8.** Single gene-based analysis: associations between RPVs in individual GPCR genes and risk of essential hypertension and MACE.

Phenotype	GPCR gene	RPVs in controls (n, %)	RPVs in cases (n, %)	OR (95% CI)	P value	P <sub>FDR</sub>	Regression model
HTN	<i>FFAR2</i>	413 (0.17%)	315 (0.21%)	<b>1.20 (1.03 - 1.40)</b>	<b>0.0109</b>	<b>0.0326</b>	model 1
				<b>1.23 (1.05 - 1.45)</b>	<b>0.0055</b>	<b>0.0326</b>	model 2
	<i>FFAR3</i>	490 (0.20%)	319 (0.21%)	1.01 (0.87 - 1.17)	0.4360	0.4990	model 1
				1.00 (0.86 - 1.17)	0.4990	0.4990	model 2
	<i>HCAR2</i>	269 (0.11%)	204 (0.13%)	1.14 (0.94 - 1.38)	0.0912	0.1611	model 1
				1.13 (0.93 - 1.38)	0.1074	0.1611	model 2
ACS	<i>FFAR2</i>	662 (0.18%)	66 (0.23%)	1.23 (0.95 - 1.60)	0.0577	0.2596	model 1
				1.25 (0.96 - 1.63)	0.0470	0.2596	model 2
				1.20 (0.92 - 1.57)	0.0877	0.2631	model 3
	<i>FFAR3</i>	747 (0.20%)	62 (0.22%)	1.01 (0.78 - 1.32)	0.4582	0.5139	model 1
				1.00 (0.76 - 1.30)	0.5139	0.5139	model 2
				1.03 (0.79 - 1.36)	0.4065	0.5139	model 3
	<i>HCAR2</i>	431 (0.12%)	42 (0.15%)	1.16 (0.84 - 1.61)	0.1870	0.3366	model 1
				1.17 (0.84 - 1.62)	0.1783	0.3366	model 2
				1.13 (0.81 - 1.57)	0.2326	0.3489	model 3
Stroke	<i>FFAR2</i>	700 (0.18%)	28 (0.23%)	1.19 (0.81 - 1.74)	0.1863	0.5230	model 1
				1.21 (0.82 - 1.77)	0.1661	0.5230	model 2
				1.17 (0.80 - 1.72)	0.2064	0.5230	model 3
	<i>FFAR3</i>	782 (0.21%)	27 (0.22%)	1.05 (0.71 - 1.54)	0.4053	0.5230	model 1
				1.06 (0.72 - 1.55)	0.3930	0.5230	model 2
				1.08 (0.73 - 1.60)	0.3459	0.5230	model 3
	<i>HCAR2</i>	457 (0.12%)	16 (0.13%)	1.02 (0.62 - 1.68)	0.4737	0.5230	model 1
				1.02 (0.62 - 1.69)	0.4650	0.5230	model 2

				0.99 (0.60 - 1.63)	0.5230	0.5230	model 3
<b>HF</b>	<i>FFAR2</i>	701 (0.18%)	27 (0.19%)	0.99 (0.67 - 1.47)	0.5102	0.5930	model 1
				0.98 (0.66 - 1.46)	0.5444	0.5930	model 2
				0.95 (0.64 - 1.42)	0.5930	0.5930	model 3
	<i>FFAR3</i>	775 (0.20%)	34 (0.24%)	1.15 (0.81 - 1.62)	0.2235	0.4151	model 1
				1.10 (0.77 - 1.58)	0.2971	0.4456	model 2
				1.14 (0.80 - 1.64)	0.2306	0.4151	model 3
	<i>HCAR2</i>	445 (0.12%)	28 (0.20%)	<b>1.62 (1.10 - 2.39)</b>	<b>0.0075</b>	<b>0.0337</b>	model 1
				<b>1.63 (1.10 - 2.42)</b>	<b>0.0071</b>	<b>0.0337</b>	model 2
				<b>1.57 (1.06 - 2.33)</b>	<b>0.0122</b>	<b>0.0365</b>	model 3
<b>MACE</b>	<i>FFAR2</i>	626 (0.18%)	102 (0.22%)	1.22 (0.98 - 1.51)	0.0403	0.1059	model 1
				1.22 (0.98 - 1.52)	0.0384	0.1059	model 2
				1.18 (0.94 - 1.48)	0.0735	0.1186	model 3
	<i>FFAR3</i>	703 (0.20%)	106 (0.23%)	1.12 (0.91 - 1.39)	0.1418	0.1596	model 1
				1.10 (0.89 - 1.37)	0.1945	0.1945	model 2
				1.14 (0.92 - 1.42)	0.1192	0.1532	model 3
	<i>HCAR2</i>	403 (0.12%)	70 (0.15%)	1.25 (0.96 - 1.63)	0.0471	0.1059	model 1
				1.26 (0.96 - 1.64)	0.0455	0.1059	model 2
				1.21 (0.93 - 1.59)	0.0791	0.1186	model 3

**Legend:** Summary statistics from multivariable logistic regression analyses testing the effect of RPV carriership status in individual GPCR genes, compared between cases and controls for each phenotype of interest. P<sub>FDR</sub>: FDR adjustment for multiple comparisons of four individual GPCR genes per phenotype.

**model 1:** adjusted for age, sex, and 10 top genetic principal components.

**model 2:** adjusted for age, sex, BMI, and 10 top genetic principal components.

**model 3:** adjusted for age, sex, BMI, 10 top genetic principal components, and SMuRFs (only for MACE subtypes analyses).

**P<sub>FDR</sub>:** FDR for multiple comparisons of three individual GPCR genes and models per phenotype.

**GPCR:** G-protein couple receptor genes; **RPVs:** Rare pathogenic variants; **HTN:** Essential hypertension; **ACS:** Acute coronary syndrome; **HF:** Heart failure; **MACE:** Major adverse cardiac events; **OR:** odds ratio; **CI:** confidence interval; **SMuRFs:** Standard modifiable cardiovascular risk factor, including smoking, HTN, diabetes, and hypercholesterolemia.

**Table S9.** Demographic and clinical characteristics of carriers and non-carriers of GPCR RPVs among cases (n=162,813).

	HTN			ACS			Stroke			HF			MACE		
	non-carriers	carriers	P value	non-carriers	carriers	P value	non-carriers	carriers	P value	non-carriers	carriers	P value	non-carriers	carriers	P value
N of participants	150,929	836		28,497	170		12,298	71		13,963	89		45,233	278	
Women (n, %)	71,208 (47.2)	376 (45.0)	0.216	7,545 (26.5)	43 (25.3)	0.794	4,850 (39.4)	27 (38.0)	0.904	4,885 (35.0)	30 (33.7)	0.888	14,769 (32.7)	88 (31.7)	0.773
Age, years (mean, SD)	59.85 (6.96)	59.89 (6.91)	0.855	61.18 (6.43)	61.22 (5.97)	0.934	61.49 (6.50)	60.52 (7.09)	0.212	62.31 (6.00)	61.87 (5.87)	0.489	61.30 (6.45)	60.98 (6.19)	0.401
BMI, kg/m <sup>2</sup> (mean, SD)	29.05 (5.08)	28.84 (5.06)	0.222	28.90 (4.75)	28.85 (4.56)	0.900	28.61 (5.00)	28.29 (5.25)	0.591	29.81 (5.73)	30.43 (6.00)	0.319	28.92 (5.03)	29.05 (5.15)	0.686
SBP, mmHG (mean, SD)	149.48 (19.41)	149.99 (20.43)	0.461	144.09 (20.23)	145.28 (21.39)	0.457	145.20 (20.73)	144.37 (20.30)	0.748	145.15 (21.37)	143.46 (21.27)	0.462	144.59 (20.39)	145.29 (21.10)	0.577
DBP, mmHg (mean, SD)	86.08 (10.85)	86.63 (11.27)	0.160	81.80 (11.19)	81.93 (11.02)	0.885	83.18 (11.27)	83.92 (10.15)	0.593	82.06 (11.67)	83.03 (11.23)	0.439	82.40 (11.22)	82.86 (11.04)	0.503
Smoking (current or past) (n, %)	57,742 (38.3)	340 (40.7)	0.163	14,031 (49.2)	94 (55.3)	0.134	5,637 (45.8)	35 (49.3)	0.643	6,975 (50.0)	42 (47.2)	0.679	21,403 (47.3)	140 (50.4)	0.341

**Legend:** P value based on a t-test (for quantitative variables) or chi-square (for qualitative variables) comparing non-carriers versus carriers.  
**ACS:** Acute coronary syndrome; **HTN:** Essential hypertension; **HF:** Heart failure; **MACE:** Major adverse cardiac events; **SD:** Standard deviation; **BMI:** Body mass index; **SBP:** Systolic blood pressure; **DBP:** Diastolic blood pressure.

**Table S10.** Significant comorbidity association in cases carrying GPCR RPVs.

Comorbidity	Phenotype	Comorbidity prevalence (%)	Comorbidity in non-carriers (n, %)	Comorbidity in carriers (n, %)	OR (95% CI) *	P value	P <sub>FDR</sub>	Regression model
Cardiomyopathy (ICD-10: I42)	HTN	1.194%	1,789 (1.2%)	23 (2.8%)	2.26 (1.50 - 3.41)	9.3x10 <sup>-5</sup>	0.0277	model 1
					2.29 (1.52 - 3.44)	7.8x10 <sup>-5</sup>	0.0277	model 2

**Legend:** Summary statistics from multivariable logistic regression analyses testing morbidity prevalence differences between GPCR RPVs carriers and non-carriers among cases for each phenotype of interest.

**model 1:** adjusted for age and sex.  
**model 2:** adjusted for age, sex, and BMI.  
**P<sub>FDR</sub>:** FDR adjustment for multiple comparisons of 297 selected ICD-10 diseases (showing a prevalence ≥1% in HTN or MACE cases) and two models (with and without BMI).

**GPCR:** G-protein couple receptor genes; **RPVs:** Rare pathogenic variants; **HTN:** Essential hypertension; **OR:** odds ratio; **CI:** confidence interval; **ICD-10:** International Classification of Disease 10<sup>th</sup> version.

**Table S11.** Demographic and clinical characteristics of carriers and non-carriers of GPCR RPVs among adequate-fiber diet consumers (n=13,858).

	<b>Adequate-fiber consumers</b> <b>(≥25g/day for women and ≥30g/day for men)</b>		
	non-carriers	carriers	P value
N of participants	13,788	70	
Women (n, %)	9,839 (71.4)	54 (77.1)	0.350
Age, years (mean, SD)	57.01 (7.84)	57.11 (7.56)	0.911
BMI, kg/m <sup>2</sup> (mean, SD)	26.47 (4.98)	26.96 (5.26)	0.411
SBP, mmHg (mean, SD)	138.58 (19.77)	140.47 (21.89)	0.445
DBP, mmHg (mean, SD)	80.66 (10.54)	81.08 (13.88)	0.749
Smoking (current or past) (n, %)	3,613 (26.2)	16 (22.9)	0.676
HTN (n, %)	<b>4,485 (32.5)</b>	<b>34 (48.6)</b>	<b>0.006</b>
ACS (n, %)	689 (5.0)	6 (8.6)	0.275
Stroke (n, %)	316 (2.3)	0 (0.0)	0.379
HF (n, %)	354 (2.6)	0 (0.0)	0.328
MACE (n, %)	1,162 (8.4)	6 (8.6)	1.000
Diabetes (n, %)	989 (7.2)	7 (10.0)	0.496
Hypercholesterolemia (n, %)	2,070 (15.0)	11 (15.7)	1.000
Any SMuRF (n, %)	7,228 (52.4)	44 (62.9)	0.104
<p><b>Legend:</b> P value based on a t-test (for quantitative variables) or chi-square (for qualitative variables) comparing non-carriers versus carriers.  <b>ACS:</b> Acute coronary syndrome; <b>HTN:</b> Essential hypertension; <b>HF:</b> Heart failure; <b>MACE:</b> Major adverse cardiac events; <b>SD:</b> Standard deviation; <b>BMI:</b> Body mass index; <b>SBP:</b> Systolic blood pressure; <b>DBP:</b> Diastolic blood pressure; <b>SMuRFs:</b> Standard modifiable cardiovascular risk factor, including smoking, HTN, diabetes, and hypercholesterolemia.</p>			

**Table S12.** Increased hypertension prevalence in GPCR RPV carriers versus non-carriers among adequate-fiber diet consumers.

Phenotype	Adequate-fiber consumers non-carriers (n=13,788)	Adequate-fiber consumers carriers (n=70)	OR (95% CI)	P value	P <sub>FDR</sub>	Regression model
<b>HTN</b>	4,485 (32.5%)	34 (48.6%)	2.14 (1.30 - 3.50)	0.0025	0.0050	model 1
			2.09 (1.25 - 3.51)	0.0052	0.0052	model 2

**Legend:** Summary statistics from multivariable logistic regression analyses testing HTN prevalence differences between GPCR RPVs carriers and non-carriers, within a subset of adequate-fiber diet consumers ( $\geq 25$ g/day for women and  $\geq 30$ g/day for men; n=13,858 subset from 168,142 with dietary data available).

**model 1:** adjusted for age and sex.  
**model 2:** adjusted for age, sex, and BMI.  
**P<sub>FDR</sub>:** FDR adjustment for two models (with and without BMI).

**GPCR:** G-protein couple receptor genes; **HTN:** Essential hypertension; **RPVs:** Rare pathogenic variants; **OR:** odds ratio; **CI:** confidence interval.